ZNTL · CIK 0001725160
Zentalis Pharmaceuticals, Inc.
What Zentalis Pharmaceuticals, Inc. owns has not been researched yet. This page is its ownership register, who holds it, and the absence of holdings below means nobody has looked rather than that there is nothing to find.
Zentalis Pharmaceuticals, Inc. - Profile
- Industry
- Pharmaceutical PreparationsSIC 2834
- Listed on
- Nasdaq
- Employees
- 106stated 2025
- Financial year ends
- 31 December
Source
Address, industry classification, listing and incorporation come from Zentalis Pharmaceuticals, Inc.'s own SEC filer record, so the industry is the SEC's dry classification rather than a marketing label. The headcount is the figure the sources below state for 2025. The description was written for this site in August 2026 from Zentalis Pharmaceuticals, Inc. Form 10-K for fiscal year 2025, Zentalis Pharmaceuticals, Inc. Form 10-Q for the quarter ended 30 June 2026, Zentalis Pharmaceuticals, Inc. Form 8-K dated 6 August 2026, Exhibit 99.1 (second quarter 2026 results and business update) and Zentalis Pharmaceuticals, Inc. Form 8-K dated 13 August 2026 (underwritten common stock offering), not taken from any single article.
Share price
ZNTL
Description
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company in San Diego, California whose sole clinical programme is azenosertib, an investigational oral, selective WEE1 inhibitor. WEE1 governs the G1-S and G2-M cell cycle checkpoints via CDK1 and CDK2: inhibiting it drives cells with damaged DNA through the cycle until the damage causes lethal mitotic catastrophe. A January 2025 strategic restructuring, since completed, narrowed the company to azenosertib, cut about 40% of the workforce and cost $7.8 million, leaving 106 full-time employees at 31 December 2025. It targets Cyclin E1-positive platinum-resistant ovarian cancer (roughly half of PROC patients by its proprietary immunohistochemistry cutoff, with a companion diagnostic in validation), an indication with FDA Fast Track designation. The registration-intended Phase 2 DENALI trial has finished enrolling Parts 2a and 2b at 400mg once daily, 5 days on and 2 days off; Part 2c is enrolling and topline data are due in the first half of 2027. The confirmatory Phase 3 ASPENOVA trial dosed its first patient in May 2026. Net loss was $137.1 million in 2025 and $77.6 million in the first half of 2026, against a $1.3 billion accumulated deficit. Cash and marketable securities of $174.6 million at 30 June 2026 gave a runway into late 2027, before an August 2026 stock offering priced to net about $75.1 million.
Who owns Zentalis Pharmaceuticals, Inc..
Nothing recorded on this side. That is a sourced finding rather than a gap where the research notes say so: see the notes below.
Select a row or a slice for its provenance: the filing it came from, when it was measured, and the arithmetic behind it if it was modelled.
The full register, from 13F filings
The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 99 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.
99 managers reported a position, together holding 43.6m shares, or 61.2% of the company. The 40 largest are listed. Percentages are of the 71.2m shares outstanding at 8 May 2026, the count in force when this quarter was measured rather than the count today.
Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.
What a reader needs to know to read these numbers
- Added 27 Aug 2026 by scripts/promote_discovered.py. This company reached the site because a covered investor holds it, not because an index listed it: it was a position in a portfolio here with no page of its own. The match was proved by requiring the register built for this CIK to contain the same CUSIP the portfolio held.
- Discovered at CUSIP 98943L107, held by bank-of-america, blackrock, bny-mellon, citigroup, fidelity-fmr, geode, goldman-sachs, invesco, jpmorgan, metlife, morgan-stanley, northern-trust, pfizer, raymond-james, state-street, vanguard, wells-fargo.
- Holdings are NOT researched. The empty holdings list means nobody has looked at what this company owns, not that it owns nothing, and the page says so.
- Shares outstanding and market cap are null rather than guessed. Neither was captured on the dated sweep that carries every other company here.
Looked for, not found
Recorded rather than filled in. Each of these is a place where a number could have been invented and was not.
- Shares outstanding.
- Market capitalisation.